Fig. 4: Best overall responses per IRC and MRD negativity rates with Isa-Kd vs Kd (ITT population). | Blood Cancer Journal

Fig. 4: Best overall responses per IRC and MRD negativity rates with Isa-Kd vs Kd (ITT population).

From: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Fig. 4: Best overall responses per IRC and MRD negativity rates with Isa-Kd vs Kd (ITT population).

A Best overall responses, and B MRD negativity rates. CR complete response, d dexamethasone, IRC independent response committee, Isa isatuximab, ITT intent to treat, K carfilzomib, MRD minimal residual disease, neg negativity, NGS next-generation sequencing, ORR overall response rate, sCR stringent complete response, VGPR very good partial response.

Back to article page